Abstract
Fetal growth restriction (FGR) presents with an increased risk of stillbirth and childhood and adulthood morbidity. Melatonin, a neurohormone and antioxidant, has been suggested as having therapeutic benefit in FGR. We tested the hypothesis that melatonin would increase fetal growth in two mouse models of FGR which together represent a spectrum of the placental phenotypes in this complication: namely the endothelial nitric oxide synthase knockout mouse (eNOS-/-) which presents with abnormal uteroplacental blood flow, and the placental specific Igf2 knockout mouse (P0+/-) which demonstrates aberrant placental morphology akin to human FGR. Melatonin (5 μg/ml) was administered via drinking water from embryonic day (E)12.5 in C57Bl/6J wild-type (WT), eNOS-/-, and P0+/- mice. Melatonin supplementation significantly increased fetal weight in WT, but not eNOS-/- or P0+/- mice at E18.5. Melatonin did, however, significantly increase abdominal circumference in P0+/- mice. Melatonin had no effect on placental weight in any group. Uterine arteries from eNOS-/- mice demonstrated aberrant function compared with WT but melatonin treatment did not affect uterine artery vascular reactivity in either of these genotypes. Umbilical arteries from melatonin treated P0+/- mice demonstrated increased relaxation in response to the nitric oxide donor SNP compared with control. The increased fetal weight in WT mice and abdominal circumference in P0+/-, together with the lack of any effect in eNOS-/-, suggest that the presence of eNOS is required for the growth promoting effects of melatonin. This study supports further work on the possibility of melatonin as a treatment for FGR.
Highlights
Fetal growth restriction (FGR), the inability of a fetus to achieve its genetic growth potential, affects between 5 and 10% of pregnancies and is a major risk factor for stillbirth (Miller et al, 2008)
There was no difference in amount of fluid drunk according to either genotype or treatment in eNOS−/− and WT mice (WT vehicle 7.6 ± 0.4, WT melatonin 6.6 ± 0.2, eNOS−/− vehicle 7.2 ± 0.5, eNOS−/− melatonin 6.8 ± 0.4, two-way ANOVA)
The curves for eNOS−/− mice treated with vehicle and melatonin were similar, but the curve for WT mice treated with melatonin was shifted to the right of the curve for WT mice receiving vehicle
Summary
Fetal growth restriction (FGR), the inability of a fetus to achieve its genetic growth potential, affects between 5 and 10% of pregnancies and is a major risk factor for stillbirth (Miller et al, 2008). Whilst there are many pathologies underlying FGR, the majority of cases are due to placental dysfunction (Baschat et al, 2007). Despite these significant antenatal and postnatal consequences of FGR, there is no treatment. The need for an effective treatment for FGR remains paramount. This lack of therapies for FGR is compounded by the fact that there is a reluctance to design drugs for obstetric conditions (Fisk and Atun, 2008). There has been a drive for the re-purposing of therapeutics, licensed for use in other clinical diseases, which may be of translational benefit to obstetric medicine
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
